Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annu...(p Oral presentation: Effects of his...)

Oral presentation: Effects of histone deacetylase (HDAC) inhibitor

PCI-24781 on the development of gallbladder carcinoma in BK5.erbB2

mice

Abstract #2447: 11:10 - 11:25 a.m.

Presenter: Kaoru Kiguchi, M.D., Ph.D., The University of Texas MD

Anderson Cancer Center

-- Session: Novel Biological Therapy Agents

Poster presentation: Levels of tonic BCR signaling predict response to

the Btk inhibitor PCI-32765

Abstract #2396: 8:00 a.m. - 12:00 p.m.

Presenter: Joseph Buggy, Ph.D., Pharmacyclics, Inc.

Tuesday, April 15, 2008

-- Session: Molecular Predictors of Drug Sensitivity and Resistance

Oral presentation: Multiple mechanisms of apoptosis induction by the

histone deacetylase inhibitor PCI-24781 lead to predictive efficacy

biomarkers

Abstract #3613: 8:00 a.m. - 12:00 p.m.

Presenter: Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.

Wednesday, April 16, 2008

-- Session: Novel Small Molecule Cancer Therapeutics 1

Oral presentation: PCI-27483, a small molecule inhibitor of Factor

VIIa, inhibits growth of BxPC3 pancreatic adenocarcinoma xenograft

tumors

Abstract #5669: 8:00 a.m. - 12:00 p.m.

Presenter: Joseph Buggy, Ph.D., Pharmacyclics, Inc.

"Our strong presence at the AACR meeting highlights the breadth of our product portfolio in cancer and autoimmune diseases," said Richard A. Miller, M.D., president and chief executive officer of Pharmacyclics. "In addition to data on our HDAC inhibitor, other presentations describe our Factor VIIa and Btk inhibitors, which we anticipate will enter clinical testing later this year."

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline
'/>"/>